Literature DB >> 21831779

Intestinal microbiota and overweight.

A Lyra1, S Lahtinen, K Tiihonen, A C Ouwehand.   

Abstract

The microbes in our gut can influence our weight by providing us with energy through the degradation of nondigestable carbohydrates and by affecting the cellular energy status of liver and muscle cells and the accumulation of lipids in adipose tissue. Thus, it is not surprising that in several studies the gastrointestinal microbiota of overweight and obese subjects has been found to differ from that of lean subjects. The initial findings linked obesity with proportionally decreased levels of the phylum Bacteroidetes and increased levels of the phylum Firmicutes. Later, several studies have assessed the association between overweight or obesity and the gastrointestinal microbiota, applying an array of molecular methods targeting the microbiota as a whole or specific bacterial groups or species within. However, at present it is difficult to draw conclusions on which of the observed microbiota alterations are relevant; essentially all of the bacterial groups that have been studied in more than one trial have given contradictory results in regard to their association with weight. Some of these discrepancies can result from methodological issues and some from the nature of the gastrointestinal microbiota, which is an extremely complex and dynamic microbial ecosystem with high subject specificity. In addition, selecting subjects purely based on weight may result in a largely heterogeneous group with several potentially confounding factors. While it may be premature to conclude which specific groups of bacteria are prominent in the intestinal tract of overweight and obese subjects, it appears clear that microbes contribute to weight gain and related health issues, such as the metabolic syndrome and type II diabetes. Therefore, it is important to continue to search for common microbial markers and predictors of obesity, and to study how these may be modulated with probiotics and prebiotics to promote health.

Entities:  

Mesh:

Year:  2010        PMID: 21831779     DOI: 10.3920/BM2010.0030

Source DB:  PubMed          Journal:  Benef Microbes        ISSN: 1876-2883            Impact factor:   4.205


  7 in total

Review 1.  Gut-Microbiota-Brain Axis and Its Effect on Neuropsychiatric Disorders With Suspected Immune Dysregulation.

Authors:  Anastasia I Petra; Smaro Panagiotidou; Erifili Hatziagelaki; Julia M Stewart; Pio Conti; Theoharis C Theoharides
Journal:  Clin Ther       Date:  2015-05-01       Impact factor: 3.393

Review 2.  Role of vitamin D on gut microbiota in cystic fibrosis.

Authors:  Mansi Kanhere; Benoit Chassaing; Andrew T Gewirtz; Vin Tangpricha
Journal:  J Steroid Biochem Mol Biol       Date:  2016-11-03       Impact factor: 4.292

3.  Infant antibiotic exposure and the development of childhood overweight and central adiposity.

Authors:  M B Azad; S L Bridgman; A B Becker; A L Kozyrskyj
Journal:  Int J Obes (Lond)       Date:  2014-07-11       Impact factor: 5.095

4.  Synbiotics in Children with Cow's Milk Allergy: A Randomized Controlled Trial.

Authors:  Hamid Ahanchian; Zahra Nouri; Seyed-Ali Jafari; Toktam Moghiman; Mohammad-Hadi Amirian; Atefeh Ezzati; Hamid-Reza Kianifar
Journal:  Iran J Pediatr       Date:  2014-01-03       Impact factor: 0.364

Review 5.  Towards microbial fermentation metabolites as markers for health benefits of prebiotics.

Authors:  Kristin A Verbeke; Alan R Boobis; Alessandro Chiodini; Christine A Edwards; Anne Franck; Michiel Kleerebezem; Arjen Nauta; Jeroen Raes; Eric A F van Tol; Kieran M Tuohy
Journal:  Nutr Res Rev       Date:  2015-06       Impact factor: 7.800

Review 6.  Gut microbiota and clinical disease: obesity and nonalcoholic Fatty liver disease.

Authors:  Ji Sook Park; Ji Hyun Seo; Hee-Shang Youn
Journal:  Pediatr Gastroenterol Hepatol Nutr       Date:  2013-03-31

7.  The Metabolism of Polysaccharide from Atractylodes macrocephala Koidz and Its Effect on Intestinal Microflora.

Authors:  Ruijun Wang; Guisheng Zhou; Mengyue Wang; Ying Peng; Xiaobo Li
Journal:  Evid Based Complement Alternat Med       Date:  2014-11-19       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.